Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder @entity5 (TURBT) vs Good-quality White Light TURBT in New Non-muscle-invasive XXXX .

@entity5 @entity1 @entity1138 @entity150
OBJECTIVE: To compare early recurrence between good-quality white-light Transurethral Resection of Bladder @entity5 (TURBT) (GQ-WLTURBT) and photodynamic diagnosis-assisted (PDD) TURBT in a real-life controlled setting. METHODS: A prospective controlled study was conducted commencing with a planned prospective cohort of @entity1 with new @entity5 undergoing white-light TURBT in 2007-2008. Previously defined principles of GQ-WLTURBT for standardization and comparison of TURBT techniques, which are (1) cystoscopic mapping using a bladder diagram, (2) documented complete resection of the @entity5 , (3) resection performed or supervised by an experienced surgeon, (4) presence of detrusor muscle in the specimen, and (5) @entity1 receiving @entity1138 within 24 hours of the resection, were applied. This was followed by a prospective cohort of new @entity1 undergoing PDD-TURBT in 2009-2011. Only @entity1 with new non-muscle-invasive @entity150 (NMIBC) deemed to have had complete first TURBT were included for analysis. Tumor features and findings at first check cystoscopy and early re-TURBT (in high-risk NMIBC) were evaluated. Early recurrence (for calculating recurrence rate at first follow-up cystoscopy) was defined as pathologically confirmed @entity5 on early re-TURBT or recurrence at the first check cystoscopy. Comparison was analyzed between GQ-WLTURBT and good-quality PDD-TURBT (GQ-PDDTURBT). RESULTS: A total of 808 @entity1 were evaluated. The overall RRFFCs for GQ-WLTURBT and GQ-PDDTURBT were 30.9% and 13.6%, respectively (odds ratio  = 2.9; 95% CI  = 1.6-5.0; P  <.001), with statistically significant lower recurrence rates in low- and intermediate-risk NMIBC after GQ-PDDTURBT. CONCLUSION: Hexvix PDD-assisted TURBT is associated with a significantly lower risk of early recurrence compared with GQ-WLTURBT in a real-life clinical setting.
